Skip to main content
SpringerLink
Log in

In vivo etoposide-resistant C6 glioma cell line: Significance of altered DNA topoisomerase II activity in multi-drug resistance

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We have established an in vivo etoposide-resistant glioma cell line (C6/VP) from C6 rat glioma cells by stepwise exposure to increasing doses of etoposide. The C6/VP cells were 10 times more resistant to etoposide than the parental C6 cells. In addition C6/VP cells demonstrated cross-resistance to vincristine and vinblastine, but not to ADM or m-AMSA. Interestingly, the cells had collateral sensitivity to ACNU, cisDDP and Ara-C. The C6/VP cells did not express the MDR gene or p-glycoprotein, while they showed 16 times less topoisomerase II catalytic activity compared to the C6 cells. Although there was no significant difference between C6 and C6/VP cells in amounts of topoisomerase II in nuclear extracts, the C6/VP cells had 2.9 times higher amounts of the enzyme than C6 cells in nuclear scaffold prepared from a relatively low-salt buffer (0.5 M NaCl). Northern blot analysis demonstrated that mRNAs of topoisomerase IIα isoforms were expressed both in C6 and C6/VP cells, and that the amounts of topoisomerase IIα in C6/VP cells were 14 times greater than in C6 cells. The total uptake of etoposide in tumor tissues derived from C6/VP cells was 3 times less than those derived from parental C6 cells. These results indicate that the C6/VP acquired a multi-drug resistance phenotype by a reduction of the catalytic activity of topoisomerase II and/or diminished accumulation of drugs. This phenotype did not involve the p-glycoprotein. Alterations of topoisomerase II in the C6/VP cells also were accompanied by an increased amount of the topoisomerase IIα isoform, most of which was localized in the nuclear scaffold (matrix). This suggests that altered binding of topoisomerase II to topologically organized DNAs in the nuclear scaffold may be the molecular basis of this multi-drug resistance phenotype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beck WT: Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerase in drug action and resistance. J Natl Cancer Inst 81: 1683–1685, 1989

    Google Scholar 

  2. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351–375, 1989

    Google Scholar 

  3. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M, Blick M: Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem 264: 16411–16420, 1989

    Google Scholar 

  4. Zwelling LA: DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev 4: 263–276, 1985

    Google Scholar 

  5. Osheroff N: Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28: 6157–6160, 1989

    Google Scholar 

  6. Robinson MJ, Osheroff N: Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4′-(9-acridinylamino) methanesulfon-m-anisidide. Biochemistry 29: 2511–2515, 1990

    Google Scholar 

  7. Zwelling LA: Topoisomerase II as a target of antileukemia drugs: A review of controversial areas. Hematol Pathol 3: 101–112, 1989

    Google Scholar 

  8. Riordan JR, Deuchars K, Kartner N, Alon N, Trent H, Ling V: Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316: 817–819, 1985

    Google Scholar 

  9. Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Rominson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 gene from multidrug resistant human cells. Cell 47: 381–389, 1986

    Google Scholar 

  10. Gros P, Ben Neriah Y, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728–731, 1986

    Google Scholar 

  11. Gros P, Croop J, Housman D: Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47: 371–380, 1986

    Google Scholar 

  12. Scotto KW, Biedler JL, Melera PW: Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 232: 751–755, 1986

    Google Scholar 

  13. Shen DW, Fojo A, Rominson IB, Chin JE, Soffir R, Pastan I, Gottesman MM: Multidrug-resistance of DNA-mediated transformants is linked to transfer of the human mdrI gene. Mol Cell Biol 6: 4039–4044, 1986

    Google Scholar 

  14. Vander Bliek A, Van der Velde-Koerts T, Ling V, Borst P: Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol Cell Biol 6: 1671–1678, 1986

    Google Scholar 

  15. Croop JM, Guikd BC, Gros P, Housman DE: Genetics of multidrug-resistance: relationship of a cloned gene to the complete multidrug-resistance phenotype. Cancer Res 47: 5982–5988, 1987

    Google Scholar 

  16. Sugimoto Y, Tsuruo T: DNA-mediated transfer and cloning of a human multidrug-resistant gene of an adryamycin-resistant myelogenous leukemia K562. Cancer Res 47: 2620–2625, 1987

    Google Scholar 

  17. Ueda K, Pastan I, Gottesman MM: Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 262: 17432–17436, 1987

    Google Scholar 

  18. Deuchars KL, Du RP, Naik M, Evernden-Porelle D, Kartner N, Van der Bliek AM, Ling V: Expression of hamster P-glycoprotein and multidrug resistance in DNA-mediated transformants of mouse LTA cells. Mol Cell Biol 7: 718–724, 1987

    Google Scholar 

  19. Raymond M, Rose E, Housman DE, Gros P: Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistance cells. Mol Cell Biol 10: 1642–1651, 1990

    Google Scholar 

  20. Silverman JA, Raunio H, Gant TW, Thorgeirsson SS: Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family. Gene 106: 229–236, 1991

    Google Scholar 

  21. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science 258: 1650–1654, 1992

    Google Scholar 

  22. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM: Pharmacological, molecular, and cytogenetic analysis of ‘atypical’ multidrug-resistant human leukemic cells. Cancer Res 47: 5455–5460, 1987

    Google Scholar 

  23. Danks MK, Yalowich JC, Beck WT: Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297–1301, 1987

    Google Scholar 

  24. Rappa G, Lorico A, Sartorelli AC: Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). Int J Cancer 51: 780–787, 1992

    Google Scholar 

  25. Friche E, Danks MK, Schmidt CA, Beck WT: Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 51: 4213–4218, 1991

    Google Scholar 

  26. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M: Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51: 3951–3957, 1991

    Google Scholar 

  27. Fernandes DJ, Danks MK, Beck WT: Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 29: 4235–4241, 1990

    Google Scholar 

  28. Feldhoff PW, Mirski SEL, Cole SPC, Sullivan DM: Altered subcellular distribution of topoisomerase IIα?in a drug-resistant human small cell Lung cancer cell line. Cancer Res 54: 756–762, 1994

    Google Scholar 

  29. Madajewicz S, Chowhan N, Iliya A, Roque C, Beaton R, Davis R, Fertman S, Meek A, Alvarez O, Pampati M, Tyson G: Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer 67: 2844–2849, 1991

    Google Scholar 

  30. Chamberlain MC: Recurrent brainstem gliomas treated with oral VP-16. J Neuro-Oncol 15: 133–139, 1993

    Google Scholar 

  31. Tsutsui K, Tsutsui K, Sakurai H, Shohmori T, Oda T: Levels of topoisomerase II and DNA polymerase alpha are regulated independently in developing neuronal nuclei. Biochem Biophys Res Commu 138: 1116–1122, 1986

    Google Scholar 

  32. Tsutsui K, Tsutsui K, Muller MT: The nuclear scaffold exhibits DNA-binding sites selective for supercoiled DNA. J Biol Chem 263: 7235–7241, 1988

    Google Scholar 

  33. Oegema TJ, Carpenter BJ, Thompson RJ: Fluorometric determination of DNA in cartilage of various species. J Orthop Res 1: 345–351, 1984

    Google Scholar 

  34. Badenoch DF, Fowler CG, Evans PR, Lowrey PA: DNA content of human semen–an objective measurement of sperm density. Br J Urol 57: 230–232, 1985

    Google Scholar 

  35. Gillery P, Bonnet A, Borel JP: A fluorometric deoxyribonucleic acid assay for tridimensional lattice cultures of fibroblasts. Anal Biochem 210: 374–377, 1993

    Google Scholar 

  36. Farina P, Marzillo G, D'Incalci M: High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma. J Chromatogr 222: 141–145, 1981

    Google Scholar 

  37. Hersh MR, Ludden TM: High-performance liquid chromatographic assay for etoposide in human plasma. J Pharm Sci 75: 815–817, 1986

    Google Scholar 

  38. Adolph KW, Chang SM, Paulson JR, Laemmli UK: Isolation of a protein scaffold from mitotic HeLa cell chromosomes. Proc Natl Acad Sci USA 11: 4937–4941, 1977

    Google Scholar 

  39. Earnshaw WC, Laemmli UK: Architecture of metaphase chromosomes and chromosome scaffolds. J Cell Biol 96: 84–93, 1983

    Google Scholar 

  40. Deffie AM, McPherson JP, Gupta RS, Hedley DW, Goldenberg GJ: Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem Cell Biol 70: 354–364, 1992

    Google Scholar 

  41. DeJong S, Zijlstra JG, de VE, Mulder NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304–309, 1990

    Google Scholar 

  42. Glisson B, Gupta R, Smallwood KS, Ross W: Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res 46: 1934–1938, 1986

    Google Scholar 

  43. Pommmier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A: Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075–3081, 1986

    Google Scholar 

  44. Estey EH, Silberman L, Beran M, Andersson BS, Zwelling LA: The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Commun 144: 787–793, 1987

    Google Scholar 

  45. Cockerill PN, Garrard WT: Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II site. Cell 44: 273–282, 1986

    Google Scholar 

  46. Gasser SM, Laemmli UK: Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes of D. melanogaster. Cell 46: 521–530, 1986

    Google Scholar 

  47. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86: 9431–9435, 1989

    Google Scholar 

  48. Tsutsui K, Tsutsui K, Okada S, Watanabe M, Shohmori T, Seki S, Inoue Y: Molecular cloning of partial cDNA for rat DNA topoisomerase II isoforms and their differential expression in brain development. J Biol Chem 268: 19076–19083, 1993

    Google Scholar 

  49. Hsiang YH, Wu HY, Liu LF: Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48: 3230–3235, 1988

    Google Scholar 

  50. Wang JC: DNA topoisomerases. Ann Rev Biochem 54: 665–697, 1985

    Google Scholar 

  51. Charros M, Hancock R: DNA topoisomerase II is required for formation of mitotic chromosomes in Chinese hamster ovary cells: studies using the inhibitor 4′-demethylepipodophyllotoxin 9-(4,6-O-thenylidene-beta-D-glucopyranoside). Biochemistry 29: 9531–9537, 1990

    Google Scholar 

  52. Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK: Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. Cancer Res 50: 2901–2908, 1990

    Google Scholar 

  53. Wood ER, Earnshaw WC: Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II. J Cell Biol 111: 2839–2850, 1990

    Google Scholar 

  54. Adachi Y, Luke M, Laemmli UK: Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell 64: 137–148, 1991

    Google Scholar 

  55. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH: Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Diff 2: 209–214, 1991

    Google Scholar 

  56. Negri C, Chiesa R, Cerino A, Bestagno M, Sala C, Zini N, Maraldi NM, Astaldi RG: Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170-and 180-kDa isozymes. Exp Cell Res 200: 452–459, 1992

    Google Scholar 

  57. Zini N, Martelli AM, Sabatelli P, Santi S, Negri C, Astaldi RG, Maraldi NM: The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. Exp Cell Res 200: 460–466, 1992

    Google Scholar 

  58. Ng WF, Sarangi F, Zastawny RL, Veinot DL, Ling V: Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 9: 1224–1232, 1989

    Google Scholar 

  59. Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM: Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51: 5275–5283, 1991

    Google Scholar 

  60. Tan KB, Mattern MR, Boyce RA, Schein PS: Unique sensitivity of nitrogen mustard-resistant human Burkitt lymphoma cells to novobiocin. Biochem Pharmacol 37: 4411–4413, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Osaka University Medical School, 2-2, Yamadaoka, Suita, Osaka, 565, Japan

    Takuyu Taki, Takanori Ohnishi, Norio Arita, Shoju Hiraga & Toru Hayakawa

Authors
  1. Takuyu Taki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takanori Ohnishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Norio Arita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shoju Hiraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toru Hayakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taki, T., Ohnishi, T., Arita, N. et al. In vivo etoposide-resistant C6 glioma cell line: Significance of altered DNA topoisomerase II activity in multi-drug resistance. J Neurooncol 36, 41–53 (1998). https://doi.org/10.1023/A:1005718912236

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005718912236

Search

Navigation